

Matthias Orth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8560990/publications.pdf>

Version: 2024-02-01

77
papers

2,003
citations

535685

17
h-index

274796

44
g-index

79
all docs

79
docs citations

79
times ranked

2523
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Implementation of the new EU IVD regulation“ urgent initiatives are needed to avert impending crisis. Clinical Chemistry and Laboratory Medicine, 2021, . | 1.4 | 18 |
| 2 | Age and sex dependent reference intervals for random plasma/serum glucose concentrations related to different sampling devices and determined by an indirect procedure with data mining. Journal of Laboratory Medicine, 2021, 45, 95-101. | 1.1 | 6 |
| 3 | Requirements for electronic laboratory reports according to the German guideline Rili-BAEK and ISO 15189. Journal of Laboratory Medicine, 2021, 45, 197-203. | 1.1 | 1 |
| 4 | Avoiding insufficient therapies and overdosing with co-reporting eGFRs (estimated glomerular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 63. benefits. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2021, 32, 41-51. | 0.7 | 0 |
| 5 | Direct to Consumer Laboratory Testing (DTCT) - Opportunities and Concerns. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2021, 32, 209-215. | 0.7 | 2 |
| 6 | Quantitative laboratory results: normal or lognormal distribution?. Journal of Laboratory Medicine, 2020, 44, 143-150. | 1.1 | 12 |
| 7 | Diagnostic work up of anemic patients: role of iron deficiency. Journal of Laboratory Medicine, 2020, 44, 175-182. | 1.1 | 1 |
| 8 | Up-to date platelet testing. Journal of Laboratory Medicine, 2020, 44, 227-230. | 1.1 | 0 |
| 9 | Autoverification of test results in the core clinical laboratory. Clinical Biochemistry, 2019, 73, 11-25. | 0.8 | 24 |
| 10 | Effects of different tube types on patient classification using current diabetes decision limits. Practical Laboratory Medicine, 2019, 17, e00134. | 0.6 | 3 |
| 11 | Opinion: redefining the role of the physician in laboratory medicine in the context of emerging technologies, personalised medicine and patient autonomy (â€“4P medicineâ€“™). Journal of Clinical Pathology, 2019, 72, 191-197. | 1.0 | 36 |
| 12 | Letter to the editor by Winter et al.: Reply. Laboratoriums Medizin, 2018, 42, 63-65. | 0.1 | 0 |
| 13 | The use of error and uncertainty methods in the medical laboratory. Clinical Chemistry and Laboratory Medicine, 2018, 56, 209-219. | 1.4 | 66 |
| 14 | Long-term medical data storage: challenges with test results obtained by direct-to-consumer testing. Laboratoriums Medizin, 2018, 42, 235-242. | 0.1 | 0 |
| 15 | Commutability Assessment of Candidate Reference Materials for Pancreatic Î±-Amylase. Clinical Chemistry, 2018, 64, 1193-1202. | 1.5 | 15 |
| 16 | Festlegung der zulÃssigen Messunsicherheit quantitativer MessgrÃ¶Ãen in der Laboratoriumsmedizin. Laboratoriums Medizin, 2017, 41, 53-58. | 0.1 | 0 |
| 17 | Der zlog-Wert als Basis fÃ¼r die Standardisierung von Laborwerten. Laboratoriums Medizin, 2017, 41, 23-32. | 0.1 | 10 |
| 18 | Standard-Arbeitsanleitung zur peripher venÃ¶sen Blutentnahme fÃ¼r die labormedizinische Diagnostik. Laboratoriums Medizin, 2017, 41, 333-340. | 0.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The zlog value as a basis for the standardization of laboratory results. <i>Laboratoriums Medizin</i> , 2017, 41, . | 0.1 | 5 |
| 20 | Direct-to-Consumer Testing. <i>Point of Care</i> , 2017, 16, 124-127. | 0.5 | 2 |
| 21 | Corrigendum zu: Chancen und Risiken von e-Health in der Labormedizin. <i>Laboratoriums Medizin</i> , 2016, 40, . | 0.1 | 0 |
| 22 | Chancen und Risiken von e-Health in der Labormedizin. <i>Laboratoriums Medizin</i> , 2016, 40, 227-237. | 0.1 | 4 |
| 23 | Recommendations for the frequency of ordering laboratory testing. <i>Laboratoriums Medizin</i> , 2015, 38, . | 0.1 | 0 |
| 24 | Are regulation-driven performance criteria still acceptable? – The German point of view. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 893-8. | 1.4 | 7 |
| 25 | Comparability and Imprecision of 8 Frequently Used Commercially Available Immunoassays for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 433-441. | 1.0 | 29 |
| 26 | Multicenter Analytical Evaluation of the Automated Electrochemiluminescence Immunoassay for Cyclosporine. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 640-650. | 1.0 | 23 |
| 27 | Empfehlungen zur Häufigkeit der Anforderung von Laboruntersuchungen. <i>Laboratoriums Medizin</i> , 2014, 38, 231-238. | 0.1 | 1 |
| 28 | Umfrage zur Laborberatung in Deutschland. <i>Laboratoriums Medizin</i> , 2014, 38, . | 0.1 | 0 |
| 29 | Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <i>Clinical Biochemistry</i> , 2014, 47, 1069-1077. | 0.8 | 32 |
| 30 | Pro und Contra der Thrombophiliediagnostik/Pros and cons of thrombophilia testing. <i>Laboratoriums Medizin</i> , 2013, 37, 67-78. | 0.1 | 1 |
| 31 | | 0.1 | 0 |
| 32 | | 0.1 | 0 |
| 33 | Einsatz der D-Dimerbestimmung – ein Update/Update of D-dimer testing. <i>Laboratoriums Medizin</i> , 2012, 36, . | 0.1 | 0 |
| 34 | Cholesterol: Its Regulation and Role in Central Nervous System Disorders. <i>Cholesterol</i> , 2012, 2012, 1-19. | 1.6 | 228 |
| 35 | Kennzahlen und Benchmarking im Krankenhauslabor/Key figures and benchmarking in the hospital laboratory. <i>Laboratoriums Medizin</i> , 2012, 36, . | 0.1 | 0 |
| 36 | Prevention of CA-MRSA. <i>Deutsches Ärzteblatt International</i> , 2012, 109, 282; author reply 282. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | CSF interleukin 6 " a useful biomarker of meningitis in adults?/ Liquor Interleukin 6 " ein sinnvoller Biomarker für die Meningitis beim Erwachsenen. <i>Laboratoriums Medizin</i> , 2011, 35, 107-113. | 0.1 | 3 |
| 38 | Antibiotika am Krankenbett. <i>Laboratoriums Medizin</i> , 2011, 35, 173-174. | 0.1 | 0 |
| 39 | Quality in Laboratory Hemostasis and Thrombosis. <i>Laboratoriums Medizin</i> , 2011, 35, 219-220. | 0.1 | 1 |
| 40 | Praktische Umsetzung des Gendiagnostikgesetzes (GenDG) in der Laboratoriumsmedizin, dem humangenetischen Laboratorium und der humangenetischen Beratung/ Practical Implications of the German Genetic Diagnostics Act (GenDG) for Laboratory Medicine, the Human Genetics Laboratory and for Genetic Counseling. <i>Laboratoriums Medizin</i> , 2011, 35, 243-253. | 0.1 | 10 |
| 41 | Unsatisfactory Quality. <i>Deutsches A&#x0308;rztblatt International</i> , 2011, 108, 129; author reply 129-30. | 0.6 | 0 |
| 42 | Thrombozytenhemmende Therapie in der Kardiologie: aktuelle Entwicklungen bei Therapie und Monitoring / Antiplatelet drugs in cardiology: current trends in therapy and monitoring. <i>Laboratoriums Medizin</i> , 2010, 34, 261-269. | 0.1 | 0 |
| 43 | Quintessence Unjustified. <i>Deutsches A&#x0308;rztblatt International</i> , 2010, 107, 215; author reply 215-6. | 0.6 | 0 |
| 44 | Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. <i>Laboratoriums Medizin</i> , 2009, 33, 121-127. | 0.1 | 0 |
| 45 | Cytokines in the Genesis and Treatment of Cancer. <i>Laboratoriums Medizin</i> , 2008, 32, 41. | 0.1 | 0 |
| 46 | cAMP-induced expression of ABCA1 is associated with MAP-kinase-pathway activation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 89-94. | 1.0 | 6 |
| 47 | Endocytosis and intracellular trafficking of fatty acid esters of phenylaminopropanediol, the putative etiologic agents of the toxic oil syndrome (TOS). <i>Toxicology Letters</i> , 2006, 163, 206-212. | 0.4 | 1 |
| 48 | Thrombophiliediagnostik bei Empfängern von Organtransplantaten / Thrombophilia diagnostics in recipients of organ transplants. <i>Laboratoriums Medizin</i> , 2004, 28, 28-33. | 0.1 | 0 |
| 49 | Chylomicron Remnant Concentrations in Patients with Coronary Artery Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 652-62. | 1.4 | 5 |
| 50 | A New Concept for Acne Therapy: A Pilot Study With Zileuton, an Oral 5-Lipoxygenase Inhibitor. <i>Archives of Dermatology</i> , 2003, 139, 668-70. | 1.7 | 96 |
| 51 | Shed L-Selectin (sCD62L) Load in Trauma Patients. <i>Journal of Surgical Research</i> , 2001, 99, 321-327. | 0.8 | 10 |
| 52 | Rapid Factor XII (46Câ't) Genotyping by Fluorescence Resonance Energy Transfer in Patients with Coronary Artery Disease or Thrombophilia. <i>Clinical Chemistry</i> , 2001, 47, 1117-1119. | 1.5 | 3 |
| 53 | An improved method for the rapid assessment of persisting chylomicron remnant concentrations. <i>Clinical Biochemistry</i> , 2001, 34, 387-394. | 0.8 | 2 |
| 54 | Postprandial chylomicrons and VLDLs in severe hypertriglycerolemia are lowered more effectively than are chylomicron remnants after treatment with nâ~3 fatty acids. <i>American Journal of Clinical Nutrition</i> , 2000, 71, 914-920. | 2.2 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Expression of Human Apolipoprotein E3 or E4 in the Brains of <i>ApoE</i> Mice: Isoform-Specific Effects on Neurodegeneration. <i>Journal of Neuroscience</i> , 1999, 19, 4867-4880. | 1.7 | 334 |
| 56 | Effects of a Frequent Apolipoprotein E Isoform, ApoE4 _{Freiburg} (Leu28 ⁺ Pro), on Lipoproteins and the Prevalence of Coronary Artery Disease in Whites. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1306-1315. | 1.1 | 38 |
| 57 | Hemostatic Factors in Hypertriglyceridemic Men. <i>Thrombosis Research</i> , 1999, 94, 341-351. | 0.8 | 2 |
| 58 | The Diagnostic Value of Serum Homocysteine Concentration as a Risk Factor for Coronary Artery Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 453-7. | 1.4 | 16 |
| 59 | Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10914-10919. | 3.3 | 331 |
| 60 | Fluorometric determination of total retinyl esters in triglyceride-rich lipoproteins. <i>Clinical Chemistry</i> , 1998, 44, 1459-1465. | 1.5 | 12 |
| 61 | Diagnostic Pitfalls during Therapy for Extreme Hypertriglyceridaemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 1997, 35, 101-3. | 1.4 | 0 |
| 62 | Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype. <i>Lipids and Lipid Metabolism</i> , 1996, 1303, 22-30. | 2.6 | 31 |
| 63 | Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth. <i>Journal of Biological Chemistry</i> , 1995, 270, 27063-27071. | 1.6 | 285 |
| 64 | Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability. <i>Thrombosis Research</i> , 1995, 79, 297-305. | 0.8 | 18 |
| 65 | Responsiveness of ATIII and coagulation factors V and VII to a standardized oral fat load. <i>Thrombosis Research</i> , 1995, 80, 265-270. | 0.8 | 3 |
| 66 | Late chylomicron remnants after a standardized oral fat load do not discriminate between patients with coronary heart disease and healthy controls. <i>Atherosclerosis</i> , 1995, 115, S8. | 0.4 | 0 |
| 67 | Postprandial heparin-induced free fatty acids discriminate between patients with and without coronary artery disease. <i>Atherosclerosis</i> , 1995, 115, S8. | 0.4 | 0 |
| 68 | Apo E and apo CIII from different lipoproteins in the HDL size range and behave differently in secondary dyslipoproteinemias. <i>Atherosclerosis</i> , 1995, 115, S69. | 0.4 | 0 |
| 69 | Lack of interference of apo(a) polymorphism in nephelometric LP(a) determination. <i>Atherosclerosis</i> , 1995, 115, S87. | 0.4 | 0 |
| 70 | Pravastatin treatment decreases postprandial levels of chylomicron remnants in type IIb patients. <i>Atherosclerosis</i> , 1994, 109, 126. | 0.4 | 0 |
| 71 | Gemfibrozil exerts favorable trends on parameters of glucose tolerance in hyperlipidemic patients suffering from diabetes mellitus. <i>Atherosclerosis</i> , 1994, 109, 249. | 0.4 | 1 |
| 72 | Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL. <i>Atherosclerosis</i> , 1992, 94, 109-117. | 0.4 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Altered concentrations, patterns and distribution in lipoproteins of serum gangliosides in liver diseases of different etiologies. Journal of Hepatology, 1990, 11, 290-296. | 1.8 | 12 |
| 74 | Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. FEBS Journal, 1989, 181, 657-662. | 0.2 | 153 |
| 75 | Biosynthesis and secretion of gangliosides by the isolated perfused rat liver. Journal of Hepatology, 1989, 9, S225. | 1.8 | 0 |
| 76 | Schnelltests: Mit Bedacht einsetzen. , 0, , . | | 2 |
| 77 | Biomarker Troponin (2): Sicht des Labormediziners. , 0, , . | | 0 |